ReviewApplied biochemistry and biotechnology2026
Metabolic Engineering for Biotechnological Production of Bioactive Methylated Flavonoids and Stilbenes: Progress and Perspectives.
Review in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Flavonoids and stilbenes are phenylpropanoid-derived secondary metabolites found in plants, fungi, and microorganisms. They serve important physiological functions and offer a range of pharmacological benefits, including antioxidant, anti-inflammatory, anticancer, and antimicrobial effects. However, many native flavonoids and stilbenes have limited pharmacology and industrial use due to poor bioavailability and low metabolic stability. O-methylation is a key post-biosynthetic modification that improves the physicochemical and pharmacokinetic properties of these compounds. This process, catalyzed by S-adenosyl-L-methionine [SAM]-dependent O-methyltransferases [OMTs], increases lipophilicity, chemical stability, and membrane permeability, often resulting in greater bioactivity. As a result, methylated derivatives such as sakuranetin, acacetin, isorhamnetin, and pterostilbene frequently show enhanced therapeutic efficacy, even though they are less abundant in nature. Advances in metabolic engineering and synthetic biology have enabled efficient biosynthesis of methylated flavonoids and stilbenes in microbial hosts such as Escherichia coli, Saccharomyces cerevisiae, and Streptomyces species. Strategies including pathway optimization, SAM regeneration, enzyme engineering, and CRISPR-based genome editing have significantly improved production yields and regioselectivity, with some systems surpassing native producers. Despite this progress, challenges remain in enzyme specificity, metabolic bottlenecks, and downstream processing. This review summarizes recent developments in understanding methylation biosynthetic pathways, OMT diversity, and microbial engineering strategies. It also highlights the pharmacological significance of methylation and the potential of engineered microbial platforms for sustainable, scalable production of methylated flavonoids and stilbenes for pharmaceutical and nutraceutical use.
Indexed as
Identifiers
41964842What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.